Share this article Share this article ResearchAndMarkets.com's offering. The therapeutic market for T1D within the 8MM will grow from $4.9B in 2019 at a significant compound annual growth rate (CAGR) of 17.2% to $24B by 2029. In particular, the publisher expects the US market will contribute the most to the T1D market's growth, contributing $4.3B sales in 2019 (87.7% of the T1D market) and $20.3B in 2029 (84.7% of the T1D market). The launch of the first disease-modifying therapeutics will be the main drivers of growth over the forecast period, with the first preventative therapeutic for T1D...